1623 Capital’s Regenxbio RGNX Stock Holding History

1623 Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,533	Closed	-$121K	–	85
2021 Q1	$121K	Buy	+3,533	New	+$151K	0.05%	67

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

1623 Capital's RGNX Position: Q2 2021 in Review

1623 Capital sold out of Regenxbio (RGNX) in Q2 2021, closing a stake of 3,533 shares — an estimated $121K sold.

1623 Capital first reported a position in RGNX in Q1 2021 and held it in 1 quarter. The position peaked at $121K in Q1 2021. 172 funds tracked by Wall St. Rank hold RGNX as of Q2 2021.

1623 Capital reported no remaining Regenxbio position as of Q2 2021 after selling out during the quarter.
1623 Capital sold 3,533 Regenxbio shares in Q2 2021, an estimated $121K.
1623 Capital first reported a position in Regenxbio in Q1 2021 and held it in 1 quarter.
1623 Capital's Regenxbio position peaked at $121K in Q1 2021.
172 funds tracked by Wall St. Rank held Regenxbio as of Q2 2021.

Based on 1623 Capital's 13F filing for Q2 2021, filed 13 Aug 2021.